Mignonne C. Guy, PhD

home / authors / mignonne-c-guy-phd

Articles

Site Logo

Telephone-Based Cardiovascular Medication Therapy Management in Medicare Part D Enrollees With Diabetes

Eleanor O. Caplan, PharmD, PhD;Mignonne C. Guy, PhD;Jean Chang, BS;Kevin Boesen, PharmD
May 10th 2017

A telephonic pharmacist-delivered medication therapy management intervention is an effective method for increasing the utilization of guideline-recommended cardiovascular therapies in high-risk Medicare patients with diabetes.

Read More

Site Logo

Cost-Effectiveness of Medication Therapy Management in Part D Diabetic Enrollees

Eleanor L. Olvey, PharmD, PhD;Mignonne C. Guy, PhD;Jean Chang;Grant H. Skrepnek, PhD
November 7th 2014

Pharmacist-delivered medication therapy management is a cost-effective method for increasing the utilization of guideline-recommended cardiovascular therapies in high-risk diabetic Medicare patients.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD